Peoples Financial Services CORP. boosted its stake in shares of Allergan PLC. (NYSE:AGN) by 7.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 730 shares of the company’s stock after buying an additional 50 shares during the period. Peoples Financial Services CORP.’s holdings in Allergan PLC. were worth $177,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Veritas Asset Management LLP bought a new stake in shares of Allergan PLC. during the first quarter valued at $761,339,000. Iridian Asset Management LLC CT boosted its stake in shares of Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares during the last quarter. Camber Capital Management LLC bought a new stake in shares of Allergan PLC. during the fourth quarter valued at $114,035,000. Renaissance Technologies LLC bought a new stake in shares of Allergan PLC. during the first quarter valued at $124,255,000. Finally, Blue Ridge Capital L.L.C. boosted its stake in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares during the last quarter. 84.77% of the stock is owned by institutional investors.
Allergan PLC. (AGN) traded up 0.29% on Friday, hitting $232.88. The stock had a trading volume of 1,820,899 shares. The company has a market cap of $77.85 billion, a P/E ratio of 7.10 and a beta of 1.16. The stock has a 50 day moving average price of $245.93 and a 200 day moving average price of $238.13. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the prior year, the business earned $3.35 EPS. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities research analysts expect that Allergan PLC. will post $16.27 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.
ILLEGAL ACTIVITY NOTICE: This article was first published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/13/allergan-plc-agn-stake-boosted-by-peoples-financial-services-corp-updated-updated-updated.html.
AGN has been the subject of several recent research reports. Zacks Investment Research raised Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a research note on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a research note on Wednesday, May 10th. Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Royal Bank Of Canada increased their price target on Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research note on Wednesday, May 10th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Eight research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $274.49.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.36% of the stock is currently owned by corporate insiders.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.